NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study

NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology (ESMO) Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma $(RCC)$ patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-243050), on October 20, 2025, and is solely responsible for the information contained therein.